MYNZ

Mainz Biomed N.V. · NASDAQ

Performance

+19.29%

1W

-23.95%

1M

-33.17%

3M

-70.97%

6M

-85.6%

YTD

-85.67%

1Y

Profile

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

Technical Analysis of MYNZ 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 36 indicating a bearish outlook, while the Oscillators Score of 56 suggests a neutral stance, and the overall Technical Score of 46 reinforces a neutral sentiment. This combination implies that while there are some bearish signals, the market is not strongly negativ...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of MYNZ

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.